- Home
- Â /Â Replimune
Replimune
Stock Price
$12.3
2024-10-29
Market Capitalization
$823.3 M
2024-10-28
Replimune Summary
Company Summary
- Overview
- Replimune is developing novel, proprietary oncolytic immunotherapies intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released.
- Type
- Public
- Status
- Active
- Founded
- 2015
- HQ
- Woburn, MA, US | view all locations
- Website
- http://www.replimune.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Philip Astley-Sparke, Chief Executive Officer & Director
Jason Rhodes, Director
Sander Slootweg, Director
Operating MetricsView all
Patients Reached
150
FY, 2018
LocationsView all
3 locations detected
Woburn, MAÂ HQ
United States
18 Commerce Way
Woburn, MA
United States
500 Unicorn Park Dr 3rd floor
Milton, England
United Kingdom
69-70 Park Dr
Replimune Financials
Summary Financials
- Net income (Q3, 2025)
- ($66.3M)
- Cash (Q3, 2025)
- $172.2M
- EBIT (Q3, 2025)
- ($66.0M)
- Enterprise value
- $698.2M